Cerenis Therapeutics and Novasep Awarded EUR 10.7M for the Development of CER-001
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and other metabolic diseases, and Groupe Novasep (Novasep), a supplier of manufacturing solutions to the life sciences industries, announced that they have received French Government funding through OSEO to finance the development of CER-001, a Cerenis HDL mimetic.
CER-001 represents a promising new approach in the fight against atherosclerotic cardiovascular disease and has shown strong preclinical efficacy in promoting reverse lipid transport, a natural cardioprotective mechanism by which excess lipids are removed from peripheral tissues and from within atherosclerotic plaques then taken to the liver for elimination. The program is currently in Phase 1 clinical development for the treatment of post-acute coronary syndrome patients.
The funding from OSEO will allow the further progression of Cerenis’ novel HDL therapy for orphan disease applications, which represent a large area of unmet need and the potential for an accelerated development pathway.
Cerenis and Novasep have collaborated on the process development for CER-001 since 2007, focusing on downstream processing of the recombinant protein component. Under this funding and an expanded agreement, Novasep will be responsible for the global manufacturing of clinical and initial commercial supplies for the orphan drug development program.
“This is an exciting step toward the development of better treatments for cardiovascular disease. Novasep has demonstrated its core expertise in protein purification to solve a manufacturing problem that has challenged the industry for decades, and we look forward to expanding our relationship,” said Jean-Louis Dasseux, President and CEO of Cerenis.
Antoine Baule, President of Novasep Process, the bioprocess division of Novasep, added “We are delighted to be working with Cerenis to further optimize the manufacturing process. There is excellent “biochemistry” between our teams and we expect to make significant progress alongside Cerenis, which is undoubtedly, one of the world experts in HDL mimetics.”
CER-001 represents a promising new approach in the fight against atherosclerotic cardiovascular disease and has shown strong preclinical efficacy in promoting reverse lipid transport, a natural cardioprotective mechanism by which excess lipids are removed from peripheral tissues and from within atherosclerotic plaques then taken to the liver for elimination. The program is currently in Phase 1 clinical development for the treatment of post-acute coronary syndrome patients.
The funding from OSEO will allow the further progression of Cerenis’ novel HDL therapy for orphan disease applications, which represent a large area of unmet need and the potential for an accelerated development pathway.
Cerenis and Novasep have collaborated on the process development for CER-001 since 2007, focusing on downstream processing of the recombinant protein component. Under this funding and an expanded agreement, Novasep will be responsible for the global manufacturing of clinical and initial commercial supplies for the orphan drug development program.
“This is an exciting step toward the development of better treatments for cardiovascular disease. Novasep has demonstrated its core expertise in protein purification to solve a manufacturing problem that has challenged the industry for decades, and we look forward to expanding our relationship,” said Jean-Louis Dasseux, President and CEO of Cerenis.
Antoine Baule, President of Novasep Process, the bioprocess division of Novasep, added “We are delighted to be working with Cerenis to further optimize the manufacturing process. There is excellent “biochemistry” between our teams and we expect to make significant progress alongside Cerenis, which is undoubtedly, one of the world experts in HDL mimetics.”
